Background: It remains unclear whether an anti-VEGF or anti-EGFR antibody with standard doublet chemotherapy is the optimal first-line treatment in patients with RAS (KRAS/NRAS ) wild-type metastatic colorectal cancer (mCRC). Here we outline the PARADIGM study (NCT02394795), designed to evaluate the superiority of panitumumab over bevacizumab, in combination with oxaliplatin/5-fluorouracil/leucovorin (mFOLFOX6) in patients with RAS wild-type chemotherapy-naïve mCRC. Patients and Methods: Eligible patients are aged 20 to 79 years with an ECOG performance status of 0-1 and histologically/cytologically confirmed RAS wild-type mCRC. A total of 800 patients are to be randomly assigned (1:1 ratio) to mFOLFOX6 plus panitumumab (n ¼ 400) or bevacizumab (n ¼ 400) and stratified according to institution, age (20-64 vs. 65-79 years), and liver metastases (present vs. absent). Each treatment regimen includes oxaliplatin 85 mg/m 2 , l-leucovorin 200 mg/m 2 , and 5-
Introduction
The treatment of metastatic colorectal cancer (mCRC) has evolved greatly over the past 2 decades. Building on backbone chemotherapy with 5-fluorouracil (5-FU)/leucovorin (LV) with oxaliplatin (FOLFOX), irinotecan (FOLFIRI), or both oxaliplatin and irinotecan (FOLFOXIRI) targeted agents have shown clinical benefit as first-line or subsequent therapy, including antiangiogenesis inhibitors (bevacizumab, ziv-aflibercept, ramucirumab); anti-epidermal growth factor receptor (anti-EGFR) antibodies (cetuximab, panitumumab); the multi-tyrosine kinase inhibitor regorafenib; and the combination agent of trifluridine/tipiracil hydrochloride (TAS-102). [1] [2] [3] [4] [5] [6] [7] Retrospective analyses of randomized clinical trials have demonstrated no survival benefit with anti-EGFR antibody therapy in patients with KRAS exon 2 mutation, or in patients with any mutation in KRAS exons 3 and 4 and NRAS exons 2, 3, and 4 8, 9 ; thus, in Western countries, cetuximab and panitumumab are indicated only in patients with wild-type RAS (Europe) or KRAS (United States).
In Japan, oxaliplatin-based therapy is more frequently selected as first-line treatment for mCRC than irinotecan-based therapy, at a similar frequency to that seen in the United States, and bevacizumab is an accepted first-line treatment regardless of RAS mutational status. 10, 11 The Japanese Society of Medical Oncology recently revised its clinical guidelines to recommend RAS mutation testing, 12 16 Given these inconsistent findings, the optimal sequencing of agents remains to be determined. Of note, it has recently been reported that the EGFR pathway is not comparably activated in left-and right-sided primary tumors, and an EGFR inhibitor-sensitive phenotype appears to be more prevalent in left-sided primary tumors, leading to the hypothesis that EGFR inhibitors may exhibit differential activity based on primary tumor location. 17 Duration of treatment is limited mainly by primary and secondary resistance. Recent evidence has suggested that in RAS wildtype mCRC, potential primary resistance mechanisms include BRAF, PIK3CA mutations, and ERBB-2 overexpression/amplification; and secondary resistance mechanisms include acquired RAS mutations, c-MET amplification, and so on. 18 Thus, there is a focus on liquid biopsy, especially for circulating tumor DNA (ctDNA) analysis that may enable comprehensive pretreatment biomarker analysis as well as resistance monitoring; a key focus of current research is development of clinically meaningful thresholds that may be used for identifying and implementing treatment changes. Evolving technologies, such as Next Generation Sequencing (NGS) and digital polymerase chain reaction, are expanding the potential of ctDNA analysis, and studies have used these in investigating resistance mechanisms against targeted therapy in mCRC. [19] [20] [21] To date, no phase III study has been conducted to prospectively compare bevacizumab and panitumumab combination therapies for RAS wild-type mCRC. The objective of the PAnitumumab and RAS, DIagnostically useful Gene Mutation for mCRC (PARA-DIGM) study (clinicaltrials.gov identifier NCT02394795) is therefore to assess mFOLFOX6 plus panitumumab or bevacizumab in the first-line treatment of RAS wild-type mCRC. Another objective is to investigate primary and secondary resistance mechanisms by collecting blood samples and archival formalin-fixed paraffin-embedded (FFPE) tissue for comprehensive biomarker analysis.
Discussion

Study Design and Treatment
The aim of the PARADIGM phase III, randomized controlled study is to assess the efficacy and safety of mFOLFOX6 þ panitumumab (experimental arm) versus mFOLFOX6 þ bevacizumab (reference arm) in the first-line treatment of chemotherapy-naïve patients with RAS wild-type, unresectable mCRC. Eligible patients are being randomized centrally in a 1:1 ratio, with randomization stratified by study site, age (20- Recommended second-line treatment for Group P is bevacizumab plus irinotecan-based chemotherapy, and for Group B, bevacizumab or anti-EGFR antibody therapy plus irinotecan-based chemotherapy. In subsequent lines, all approved drugs are recommended as appropriate across the 2 groups. This study is being conducted according to the ethical principles laid down in the Declaration of Helsinki Ethical Guidelines for Clinical Research, and the International Conference on Harmonisation E6 Good Clinical Practice. The ethical committee or institutional review committee at each site approved the protocol before the initiation of the site. All patients are required to sign written informed consent.
Patients
Eligibility criteria are shown in Table 1 . RAS testing is done using the validated in vitro diagnosis method that covers both KRAS and NRAS codons 12, 13, 59, 61, 117, and 146, all of which must be determined to be wild-type in the tumor using archival FFPE tissue to be eligible. Patients can receive adequate supportive care for neutropenia, nausea, vomiting, allergic reaction, hypertension, and interstitial lung disease. For panitumumab-related skin toxicities, the following supportive care is strongly recommended: tetracycline antibiotic, external salicylic acid petrolatum, steroid ointment, moisturizer, or sunscreen.
Endpoints and Assessments
The primary endpoint is OS, defined as time from randomization until death from any cause. Secondary endpoints include progression-free survival (time from randomization until documented progressive disease or death from any cause), response rate, duration of response, percentage of curative resection (R0 resection), and safety. Response is being assessed according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
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Adverse events are being graded according to the Common Terminology Criteria for Adverse Events (Japanese edition, JCOG version v4.03). Exploratory endpoints include percentage of early tumor shrinkage, defined as a !20% decrease from baseline in the sum of longest diameter of the target lesions at week 8 by enhanced computed tomography; and maximum tumor shrinkage (depth of response), which also will be determined based on change in the sum of longest diameter of the target lesions. 
Target Sample Size and Statistical Analysis Plan
For assessment of the difference in OS, a piecewise exponential distribution will be assumed, in which the survival rate of the 2 treatment groups would be the same until 18 months, and then after 48 months would be 22% and 32% for the bevacizumab and panitumumab groups, respectively. To detect an OS hazard ratio of 0.76 based on the log-rank test with a 1-sided significance level of 2.5%, 570 death events will ensure a power of approximately 80%, requiring accrual of 800 patients over a 24-month enrollment period, and a 36-month follow-up period. An interim analysis for OS is planned when 70% (399 events) of the targeted number of events are observed. If the primary endpoint is met, subgroup 
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analysis of patients with left-sided primary tumors will be performed.
Comprehensive Biomarker Analysis
Archival FFPE tumor tissue and ctDNA samples taken before treatment and at confirmed progressive disease will be collected in a large-scale biomarker analysis study (NCT02394834), with the aim of investigating potential biomarker candidates related to both primary and secondary resistance mechanisms. Matched pretreatment DNA from primary tissue and ctDNA will be analyzed by a NGS-based platform to investigate potential biomarkers of primary resistance mechanisms, and pre-and posttreatment ctDNA will be analyzed to investigate potential secondary mechanisms of resistance for each treatment arm. An ultra-deep target sequencing panel will be developed using molecular tagging specifically designed for the CRC ctDNA assay; exons of more than 70 genes will be captured so that point mutations and copy number variations can be detected. Genes will be selected to cover previously identified CRC-related pathways (RTK-RAS pathway, WNT pathway, transforming growth factor-beta pathway), CRC-related biological processes (DNA damage repair, CpG island methylation), 23, 24 and pathways presumed relevant to acquired resistance of EGFR-targeted therapies (apoptosis, JAK-STAT). 21, 25 For archived FFPE samples, a conventional target sequencing panel covering approximately 1000 cancer-related gene exons will be designed to explore a wider range of potential predictive genome biomarkers.
Conclusion
PARADIGM is the first phase III study to prospectively restrict eligibility to RAS wild-type patients and the chemotherapy regimen to mFOLFOX6, to conduct a head-to-head comparison of panitumumab versus bevacizumab, and to incorporate a prespecified subgroup analysis of patients with left-sided primary tumors. The first patient was enrolled in May 2015; 250 sites in Japan are currently open for enrollment. The estimated completion date is 2020. The findings will help to establish the optimal combination of a monoclonal antibody (anti-vascular endothelial growth factor vs. anti-EGFR) in the first-line treatment of patients with mCRC.
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